Skip to main content
Ensol Biosciences Inc. logo

Ensol Biosciences Inc. — Investor Relations & Filings

Ticker · 140610 ISIN · KR7140610007 KO Manufacturing
Open in API
Filings indexed 257 across all filing types
Latest filing 2020-08-13 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 140610

About Ensol Biosciences Inc.

https://www.ensolbio.co.kr/eng/

Ensol Biosciences Inc. is a biopharmaceutical company focused on developing innovative drugs for diseases with limited or no therapeutic alternatives. The company leverages a bio big data and AI-driven platform for its research and development activities. A core area of its technology involves Protein-Protein Interaction (PPI)-regulating short peptide drugs, which are designed for local injection to maximize therapeutic effects and minimize systemic side effects through high specificity and a short half-life in the blood. The company's pipeline targets a range of medical unmet needs, including degenerative disc disease, osteoarthritis, cancer, and neurodegenerative disorders like Alzheimer's disease. Key clinical-stage assets include E1K for osteoarthritis (preparing for Phase 3) and C1K, an anticancer combination therapy (Phase 1).

Recent filings

Filing Released Lang Actions
[기재정정]주주명부폐쇄기간또는기준일설정
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing regarding the suspension of stock name changes (shareholder register closure) due to a merger. It is a formal corporate announcement filed with a regulatory body (DART in Korea). Since it does not fit into specific categories like dividend announcements or director dealings, and is a standard regulatory disclosure, it falls under the RNS (Regulatory Filings) category.
2020-08-13 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding the scheduling of an Investor Relations (IR) meeting. It provides details such as the date, time, location, purpose, and target audience for the upcoming event. Since it is an announcement of an event rather than the presentation materials themselves, and it does not fit into other specific categories like M&A or financial reports, it is classified as a Regulatory Filing (RNS) which serves as the standard category for such corporate event notifications in this schema.
2020-08-10 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) submitted to the Financial Services Commission/Korea Exchange. It details the issuance of stock options to employees and executives, including the number of shares, exercise price, and valuation methodology. Since this is a specific regulatory disclosure regarding capital/equity-related instruments that does not fit into the other categories like 'Director's Dealing' (which is for personal trades) or 'Share Issue' (which is for general capital changes), it is classified as a Regulatory Filing (RNS).
2020-08-06 Korean
주주명부폐쇄기간또는기준일설정
Share Issue/Capital Change Classification · 100% confidence The document is a short regulatory notice regarding the suspension of share registration (shareholder register closure) due to a merger. It is a specific corporate action announcement rather than a full report, and it does not fit into the specific categories for dividends, share buybacks, or director dealings. Given its nature as a regulatory notification of a corporate event, it falls under the general regulatory filing category.
2020-08-06 Korean
[첨부추가]주요사항보고서(회사합병결정)
M&A Activity Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange regarding a corporate merger (회사합병 결정) between Ensol Biosciences and its subsidiary Pison Science. This type of regulatory filing detailing M&A activity, merger ratios, and legal justifications for the transaction falls under the M&A Activity category.
2020-08-06 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/Korea Exchange). This document details the shareholdings and changes in ownership by a company director (Bae Jungdon) of Ensol Biosciences. In the context of financial filings, reports detailing personal share transactions by company directors and executives are classified as 'Director's Dealing'.
2020-08-05 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.